Upsarin UPSA tabs 500mg #16

Instruction for Upsarin UPSA

You can buy Upsarin UPSA on this page

Composition

1 effervescent tablet contains in its composition active substance acetylsalicylic acid in an amount of 500 mg, as well as additional components: citric acid, aspartame, sodium carbonate and hydrogen carbonate, povidone, crospovidone, sodium citrate, flavor.

Form of issue

Effervescent tablets.

pharmachologic effect

Non-steroidal anti-inflammatory drug.

Pharmacodynamics and pharmacokinetics

Principle of action Upsarin UPSA is based on an indiscriminate decrease in the activity of cyclooxygenases 1 and 2, which take an active part in the synthesis of prostaglandins (they form a pain syndrome and swelling in the area of ​​inflammation).
The medication has analgesic, anti-inflammatory, moderately expressed antipyretic effects.
The active substance is acetylsalicylic acid. With a decrease in the concentration of prostaglandins in the area of ​​thermoregulation, body temperature decreases due to increased sweating and widening of the lumen of blood vessels. The analgesic effect is achieved by the central and peripheral action of acetylsalicylic acid. The drug suppresses the synthesis of thromboxane A2 in platelet cells, reducing thrombosis, adhesion and aggregation of platelets. After a single dose of Uppsarin Oops, the antiplatelet effect achieved can persist for seven days (the severity of this effect is stronger in males than in females).
The medication reduces the risk of developing myocardial infarction and the death rate when diagnosing unstable angina pectoris. Effectively used in predisposed persons for primary and secondary prevention of myocardial infarction. At a dose of 6 grams per day increases the prothrombin time and simultaneously inhibits the formation of prothrombin in the hepatic system.
Upsarin UPSA can reduce the level of vitamin K-dependent clotting factors (2,7,9,10), increases the fibrinolytic activity of plasma. Against the backdrop of treatment with a drug, the risk of bleeding and hemorrhagic complications increases significantly during surgical interventions.
Due to disruption of reabsorption of uric acid in the tubules of the renal system, acetylsalicylic acid stimulates its excretion.
The drug reduces the activity of gastroprotective (protective) prostaglandins, blocks cyclooxygenase-1, which may serve as an excuse for ulceration of the gastric mucosa with subsequent bleeding. It is recommended to give preference to dosage forms that contain a special enteric coating, buffer substances.
The additional form of the drug is available - Upsarin UPSA with vitamin C. It is a complex preparation that contains ascorbic and acetylsalicylic acids. Vitamin C takes an active part with oxidation and reduction processes, regulates blood coagulability, the process of synthesizing various substances and carbohydrate metabolism. Ascorbic acid has a pronounced antioxidant effect and increases the regenerative capacity of tissues.

Indications for use Upsarin UPSA

From what tablets are appointed?

The medication is prescribed for pain syndrome: neuralgia, headaches, myalgia, lumbago, toothache, algodismenorea, arthralgia, radicular syndrome.
The drug Upsarin UPSA is used to relieve a mild febrile syndrome, which accompanies many diseases of an infectious and inflammatory nature.
In the case of unstable angina pectoris, painless form of myocardial ischemia, with myocardial infarction, in diagnosing several risk factors for coronary heart disease, after prosthetic heart valves, after coronary balloon angioplasty, after the installation of a special stent, for aortoarteritis, for lesions of coronary arteries of non-atherosclerotic origin mitral valve prolapse, Dressler's syndrome, acute thrombophlebitis, pulmonary infarction Upsarin UPSA is prescribed as an antiplatelet agent in c the daily dose to 300 mg.

Contraindications

Various hemorrhagic diatheses (thrombocytopenic purpura, hemophilia, hypoprothrombinemia, telangiectasia, von Willebrand disease), the presence of an "aspirin triad" (simultaneous diagnosis of recurrent form of nasal polyposis and adjacent sinuses, bronchial asthma and intolerance to pyrazolone series, acetylsalicylic acid).
The drug is not prescribed for erosive and ulcerative pathology of the mucous walls of the digestive tract (acute stage, exacerbation), with intolerance to the active component, vitamin K deficiency, pregnancy bearing, severe liver pathology and renal system.
The use of Upsarin by UPSA during breastfeeding is contraindicated.
With ulcerative lesions of the digestive system in anamnesis, with decompensated form of CHF, gout, hyperuricemia, nephrourolythiaz (urate form), Upsarin UPSA is used with caution (additional experts are required), assessing possible risks and long-term consequences.

Side effects

As a result of the hapten mechanism, "aspirin asthma" and "aspirin triad" (including a simultaneous combination of nasal polyposis, contiguous sinuses, bronchial asthma and intolerance to pyrazolone and acetylsalicylic acid preparations) are formed.
Perhaps the development of allergic responses in the form of bronchospasm, various rashes on the skin, angioedema.
A drug may cause disturbances in the functioning of the kidneys and the hepatic system. Long-term therapy causes vomiting, dizziness, hypocoagulation, interstitial nephritis, bronchospasm, erosive ulcerative lesions of the digestive system (stomach, duodenum), tinnitus, visual and auditory impairment, papillary necrosis, prerenal azotemia with hypercalcemia and elevated creatinine, the severity of clinical symptoms of CHF, aseptic meningitis, nephrotic syndrome, puffiness.

Upsarin UPSA, instructions for use (Method and dosage)

Treatment of acute rheumatism: the daily dose is calculated according to the scheme of 100 mg per 1 kg of weight per day, the frequency of reception is 5-6 times a day.
Painful and febrile syndrome: 500-100 mg per day, divided into three doses. The course of therapy is not more than two weeks.
How to take Upsarin UPSA: effervescent tablets should be taken after meals, previously dissolved in water (100-200 ml), 3-4 times a day. The duration of therapy can vary from 1 day to several months. They take 150-250 mg of acetylsalicylic acid per day, which improves the rheological properties of the blood.
According to the instructions for use of Upsarin UPSA, patients who underwent myocardial infarction, as well as for secondary prevention, are recommended to take 40-325 mg of the drug daily (average dose is 160 mg). To inhibit the aggregation of platelets, 300-325 mg of medication are prescribed daily.
The method of application of Upsarin UPSA in cerebral thromboembolism, with dynamic changes in cerebral circulation: the initial dose is 325 mg per day, further it is recommended to gradually increase the amount of the drug to 1000 mg per day. Admission of 125-300 mg per day provides prevention of relapse. The intake of 325 mg of acetylsalicylic acid every seven hours through a special gastric tube (installed intranasally) provides prevention of occlusion of the aortic shunt and its thrombosis. Further it is recommended to switch to oral medication forms: three times a day at a dose of 325 mg in a complex therapy with Dipiridamole within a week.

Overdose

It is manifested by central hyperventilation of the lungs, bleeding, anuria, respiratory alkalosis, collapse, drowsiness, metabolic acidosis and confusion.
At the initial stage, hyperventilation of the lungs leads to respiratory alkalosis: cyanosis of limbs and body, suffocation, shortness of breath, the appearance of cold, sticky sweat. Further, as a result of increased intoxication, respiratory paralysis develops and complete dissociation in oxidative phosphorylation, which ultimately leads to respiratory acidosis.
When poisoning is recommended, provocation of vomiting, the appointment of laxatives, enterosorbents, activated carbon. Control over the electrolyte balance is mandatory. If necessary, a solution of lactate, citrate or sodium bicarbonate is administered.
Increase the excretion of acetylsalicylic acid by increasing the reserve alkalinity. For alkalinization of urine, it is not recommended to use acetazolamide (possible development of acidemia, increased toxic effect of acetylsalicylic acid).
In elderly people, intensive infusion therapy can lead to pulmonary edema, which must be taken into account when treating intoxication with UPPSAR.
Hemodialysis is prescribed at a medication level of more than 100-130 mg%.
With the development of pulmonary edema, it is recommended to carry out artificial ventilation with a special mixture rich in oxygen.

Interaction

Upsarin UPSA increases the concentration of lithium salts, barbiturates and digoxin in blood plasma.
Ethanol-containing medicines, glucocorticosteroids, ethanol increase the irritating effect of acetylsalicylic acid on the mucous walls of the digestive tract (the likelihood of gastrointestinal bleeding increases significantly).
The drug improves the effectiveness of reserpine, non-steroidal anti-inflammatory drugs, thrombolytic agents, indirect anticoagulants, sulfonamides (eg, Co-Trimoxazole), narcotic analgesics, platelet aggregation inhibitors, hypoglycemic agents (oral forms).
The drug increases the toxic effect of methotrexate.
Instructions for use Upsarin UPSA it is not recommended to prescribe medicament simultaneously with diuretic (verospiron, furosemide), hypotensive, uricosuric agents (sulfinpyrazone, benzbromarone).
The speed and quality of absorption of acetylsalicylic acid decreases with the use of antacid agents, in which the salts of magnesium and aluminum descend.

Terms of sale

To buy Upsarin UPSA the prescription is not requered.

Storage conditions

In a dry place inaccessible to children at a temperature of no more than 30 degrees Celsius.
Shelf life not more than three years.

special instructions

Long-term treatment with Upsarin UPSA requires mandatory control over the main indicators of blood condition, regular examination of feces for latent blood.
When using the drug as an anesthetic, acetylsalicylic acid can be taken no longer than a week. To achieve antipyretic effect, the drug can be used for no more than three days.
It is recommended to completely discard salicylates 7 days before the planned surgical intervention. The use of Upsarin UPSA in pediatric practice in viral pathology is contraindicated because of the risk of developing Reye's syndrome (increased liver size, the formation of acute encephalopathy, indomitable vomiting).
Thorough grinding tablets, taking medication after meals, using enteric-soluble forms of acetylsalicylic acid, using drugs that neutralize the increased acidity of gastric juice, can reduce the irritating effect of the drug Upsarin UPSA on the mucous walls of the digestive tract.
The drug can provoke a predisposition to a new attack of gout. Such an effect is explained by a decrease in the amount of uric acid withdrawn during the treatment with medication.
Acetylsalicylic acid is excreted in breast milk, increasing the risk of bleeding in infants due to functional changes in blood platelets.
The teratogenic effect of the medication is manifested by hypertension in the "small" circle of blood circulation, hyperplasia of the vessels of the lung tissue, premature closure of the lumen of the arterial duct.

In pregnancy

Application of the drug Upsarin UPSA during pregnancy leads to the formation of malformations (cleavage of the upper palate) in the first trimester, and reduces the rate of labor in the third trimester due to inhibition of the synthesis of prostaglandins.

With alcohol

Alcohol and Upsarin UPSA are pharmacologically incompatible (requires complete refusal to drink alcohol-containing beverages).

Reviews about Upsarin UPSA

According to reviews, the drug is effective according to indications when the instructions for use are followed.